Business, energy, technology, markets and global industry news from Business News Today

ASCENT-04

PharmaDeviceNews ASCENT-04
A patient receives infusion-based breast cancer care as clinicians review treatment imaging, reflecting the CHMP recommendation for Gilead Sciences’ Trodelvy plus Keytruda in first-line PD-L1-positive metastatic triple-negative breast cancer. Representative image.
Pharma & Biotech

Gilead’s Trodelvy cleared a key EU hurdle, but can it really replace chemotherapy in first-line TNBC?

CHMP backs Trodelvy plus Keytruda for first-line PD-L1-positive metastatic TNBC, moving Gilead closer to an expanded EU label.

Read More
Representative image: An oncology specialist reviews treatment information with a breast cancer patient in a clinical setting, reflecting Gilead Sciences’ Trodelvy regulatory progress in first-line metastatic triple-negative breast cancer care.
Pharma & Biotech

Gilead’s Trodelvy gains EU regulatory momentum, but the first-line TNBC fight is only beginning

Gilead’s Trodelvy may move earlier in metastatic TNBC. The EU signal could reshape first-line ADC use, but adoption questions remain.

Read More